The essential P. aeruginosa pan-genome during chronic infection
慢性感染过程中必需的铜绿假单胞菌全基因组
基本信息
- 批准号:8623447
- 负责人:
- 金额:$ 24.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-12-01 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:Acinetobacter baumanniiAcuteAddressAntibioticsBacteriaBacterial InfectionsBehaviorBiologyBurn injuryChronicClinicalDevelopmentDiseaseDoseEndocarditisEnvironmentFamily suidaeFutureGenesGenetic DeterminismGenomeGenomicsGrowthHealthHealthcareHumanImmune systemImmunityInfectionKnowledgeLearningLifeLinkMethodologyMicrobeMicrobial BiofilmsMissionModelingMolecularNatureOperative Surgical ProceduresOrganismPathogenesisPathway interactionsPseudomonas aeruginosaPublic HealthSamplingSiteStaphylococcus aureusSwimmingTestingThickTimeUnited States National Institutes of HealthWorkWound HealingWound Infectionburden of illnessdesigndisabilityenhancing factorin vivoinformation gatheringinsightnovelnovel strategiespathogenpublic health relevanceresearch studytreatment strategywound
项目摘要
DESCRIPTION (provided by applicant): This application seeks to address the impact of bacterial colonization and persistence in chronic wounds. The formation of biofilms has clearly been linked to chronic and persistent bacterial infections. This considerably delays and complicates wound healing. Unlike acute bacterial infections, which are often cleared by the host, biofilm-related chronic infections are not easily resolved even with high dose antibiotics and intact immunity. The bacterial pathogens Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus, which are the focus of this application, cause an array of biofilm-related clinical diseases including persistent airway infections, burn wound infections,
endocarditis, and surgical site infections. Unresolved infected wounds also contribute to nosocomial persistence and the spread of bacteria in health care settings. This proposal will use state-of-the art molecular and genomic approaches to define genes and pathways essential for P. aeruginosa persistence in chronic wounds in monoculture as well as in the presence of S. aureus and/or A. baumannii. Investigating this hypothesis will allow us to learn new P. aeruginosa biology and aid future management and treatment of chronic infections. Aim 1 will identify genes and pathways necessary for P. aeruginosa during a chronic wound infection. Aim 2 will identify genes and pathways necessary for P. aeruginosa during polymicrobial chronic wound infections. The development of a chronic infection model that can be sampled over time provides a relevant, unique, and novel approach for examining the effects of biofilm formation in the host. Ultimately information gathered will aid the treatment of an array of chronic infections including highly prevalent persistent wound infections.
描述(由申请人提供):本申请旨在解决慢性伤口中细菌定植和持久性的影响。生物膜的形成显然与慢性和持续的细菌感染有关。这大大延迟了伤口愈合。与通常由宿主清除的急性细菌感染不同,即使使用高剂量抗生素和完整的免疫力,与生物膜相关的慢性感染也不容易解决。细菌病原体是铜绿假单胞菌,鲍曼尼杆菌和金黄色葡萄球菌(这是该应用的重点)引起一系列与生物膜相关的临床疾病的重点
心内膜炎和手术部位感染。未解决的感染伤口也有助于医疗保健环境中细菌的医生持久性和细菌的传播。该建议将使用最先进的分子和基因组方法来定义单一培养物以及金黄色葡萄球菌和/或Baumannii的慢性伤口中铜绿假单胞菌持久性必不可少的基因和途径。研究这一假设将使我们能够学习新的铜绿假单胞菌生物学,并帮助对慢性感染的未来管理和治疗。 AIM 1将在慢性伤口感染期间鉴定铜绿假单胞菌所需的基因和途径。 AIM 2将确定多因素慢性伤口感染期间铜绿假单胞菌所必需的基因和途径。可以随着时间的推移进行采样的慢性感染模型的开发提供了一种相关,独特和新颖的方法,用于检查宿主中生物膜形成的影响。最终收集的信息将有助于治疗一系列慢性感染,包括高度普遍的持续伤口感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel J Wozniak其他文献
Daniel J Wozniak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel J Wozniak', 18)}}的其他基金
The impact of bacteriophage therapy on wound infection dynamics
噬菌体疗法对伤口感染动态的影响
- 批准号:
10467125 - 财政年份:2022
- 资助金额:
$ 24.43万 - 项目类别:
The impact of bacteriophage therapy on wound infection dynamics
噬菌体疗法对伤口感染动态的影响
- 批准号:
10560606 - 财政年份:2022
- 资助金额:
$ 24.43万 - 项目类别:
Conserved complement binding to bacterial porins
与细菌孔蛋白结合的保守补体
- 批准号:
8772309 - 财政年份:2014
- 资助金额:
$ 24.43万 - 项目类别:
The essential P. aeruginosa pan-genome during chronic infection
慢性感染过程中必需的铜绿假单胞菌全基因组
- 批准号:
8780593 - 财政年份:2013
- 资助金额:
$ 24.43万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
- 批准号:22304039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
- 批准号:82360957
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:地区科学基金项目
相似海外基金
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms
开发一类针对碳青霉烯类耐药革兰氏阴性生物的新型肽抗生素
- 批准号:
10674131 - 财政年份:2023
- 资助金额:
$ 24.43万 - 项目类别:
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’
开发广谱替克菌素-脂肽杂合体,用于治疗泛耐药“超级细菌”引起的肺部感染
- 批准号:
10650420 - 财政年份:2022
- 资助金额:
$ 24.43万 - 项目类别:
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
- 批准号:
10708102 - 财政年份:2022
- 资助金额:
$ 24.43万 - 项目类别:
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’
开发广谱替克菌素-脂肽杂合体,用于治疗泛耐药“超级细菌”引起的肺部感染
- 批准号:
10503471 - 财政年份:2022
- 资助金额:
$ 24.43万 - 项目类别:
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
- 批准号:
10587015 - 财政年份:2022
- 资助金额:
$ 24.43万 - 项目类别: